Topic: antibody-drug conjugates
The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
NBE will use the money to start testing anti-ROR1 antibody-drug conjugate NBE-002 in solid tumor patients.
Celldex culled another two R&D projects after its midstage failure in April, and now says it will focus its efforts mainly on two cancer antibodies.
AbbVie has terminated an early-stage trial of an antibody-drug conjugate for solid tumors.
ADC Therapeutics has dropped a midpipeline candidate for HER2-positive cancers because of toxicity issues in a phase 1 trial in solid tumors.
AstraZeneca is seeking approval of moxetumomab pasudotox in HCL patients who have undergone at least two prior lines of treatment.
Pfizer is backing out of its $635 million armed antibody tech deal with CytomX.
Magenta could pay the German biotech up to $334 million in milestones if the antibody drug conjugate pacts hit their targets.
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.